Syndax Pharmaceuticals (SNDX) Consolidated Net Income: 2015-2024
Historic Consolidated Net Income for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to -$318.5 million.
- Syndax Pharmaceuticals' Consolidated Net Income fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$318.5 million for FY2024, which is 52.40% down from last year.
- Per Syndax Pharmaceuticals' latest filing, its Consolidated Net Income stood at -$318.5 million for FY2024, which was down 52.40% from -$209.0 million recorded in FY2023.
- In the past 5 years, Syndax Pharmaceuticals' Consolidated Net Income ranged from a high of $24.7 million in FY2021 and a low of -$318.5 million during FY2024.
- In the last 3 years, Syndax Pharmaceuticals' Consolidated Net Income had a median value of -$209.0 million in 2023 and averaged -$225.5 million.
- In the last 5 years, Syndax Pharmaceuticals' Consolidated Net Income soared by 133.90% in 2021 and then tumbled by 702.74% in 2022.
- Syndax Pharmaceuticals' Consolidated Net Income (Yearly) stood at -$72.9 million in 2020, then soared by 133.90% to $24.7 million in 2021, then plummeted by 702.74% to -$149.0 million in 2022, then plummeted by 40.25% to -$209.0 million in 2023, then crashed by 52.40% to -$318.5 million in 2024.